The 0.70 Cutoff in COPD Diagnosis: Fixed Ratio Versus Lower Limit of Normal

When one number decides who has COPD

GOLD keeps a fixed post-bronchodilator FEV1/FVC below 0.70 as the spirometric definition of chronic obstructive pulmonary disease because a single threshold is reproducible, easy to teach, and does not move with whichever reference equation a laboratory happens to load. The trade-off is built into human biology. The ratio of forced expiratory volume in one second to forced vital capacity falls naturally as lungs age, so a fixed 0.70 labels some healthy older adults as obstructed while missing early disease in younger ones, whose normal ratio sits well above 0.70. A lower-limit-of-normal (LLN) cutoff corrects for age, height, sex, and reference population, yet it depends on the equation chosen and has not clearly outperformed 0.70 at predicting who is hospitalized or dies. The 2025 GOLD report resolves the tension by holding 0.70 as the anchor while urging clinicians to check the LLN in exactly the patients the fixed ratio is most likely to misclassify.

What the two cutoffs actually measure

Spirometry after a bronchodilator gives two numbers that define obstruction: how much air a person can force out in the first second (FEV1) and how much they can exhale in total (FVC). A low ratio means air is being trapped. The fixed cutoff draws the line at 0.70 for everyone. The LLN instead compares a person's ratio against a healthy reference population of the same age, height, and sex, and flags results below the fifth percentile, which corresponds to a z-score of about -1.645. Those reference values come from large datasets such as the Global Lung Function Initiative 2012 equations, built from more than 70,000 healthy nonsmokers spanning ages 3 to 95, published by Quanjer and colleagues in the European Respiratory Journal.

Why 0.70 drifts wrong at both ends of adulthood

Healthy lungs lose elastic recoil with age, and FVC holds up better than FEV1, so the ratio slides downward across a normal lifespan. By the seventies and eighties, the true fifth percentile in never-smokers can dip below 0.70. A fixed cutoff therefore counts ordinary aging as disease and overdiagnoses older adults. The same physics runs in reverse in young adults, whose healthy ratio may sit around 0.80 or higher. A person in their thirties with genuine early obstruction can post a ratio of 0.72, above the fixed line yet below their own LLN, and be told their lungs are fine. GOLD acknowledges both errors in the 2025 report, and its added guidance for younger patients reflects concern about missing early disease in that group.

The case GOLD makes for holding the line

The defense rests on three points. First, the fixed ratio is one number that any clinic can apply without loading population-specific software. Second, and more decisively, it holds up against hard outcomes. In a large pooled analysis of more than 24,000 US adults published in JAMA in 2019, Bhatt and colleagues followed participants for a median of 15 years and found that defining obstruction as FEV1/FVC below 0.70 discriminated COPD-related hospitalization and death as well as or better than the LLN; the empirically optimal threshold landed at 0.71, statistically indistinguishable from 0.70. Third, GOLD does not treat spirometry as a standalone verdict. Its Science Committee, writing in the European Respiratory Journal in 2025, stressed that a diagnosis requires symptoms and an exposure such as tobacco or biomass smoke, and that confirmatory post-bronchodilator testing further trims false positives. That review noted that overdiagnosis estimates ranging from roughly 11 to 35 percent across cohorts shrink once symptoms and risk factors are required rather than a spirometry printout alone.

The wrinkle the LLN cannot escape

The LLN sounds like an objective correction, but it is only as fixed as the equation behind it. Switch to a different reference population and the line moves with it. That became concrete in 2023, when the American Thoracic Society recommended race-neutral interpretation using the GLI Global equation, which averages across ancestry groups rather than applying separate coefficients. The change shifts predicted values and LLN thresholds for many patients, reclassifying some as obstructed and others as normal without any change in their actual lungs. This is the quiet weakness of an individualized cutoff: it inherits every assumption baked into its reference model, and those assumptions are still being revised.

What the 2025 report asks clinicians to do

GOLD's practical answer is to use both tools rather than crown one. The fixed 0.70 remains the diagnostic anchor for consistency and outcome prediction, while the LLN or z-score serves as a cross-check in the groups where the fixed ratio is least trustworthy. The report specifically suggests that for adults under 50 with a borderline ratio at or just above 0.70, comparing against the predicted LLN or z-score can prevent a missed diagnosis, and that in older adults the LLN can temper an overcall. The number on the report is the start of a clinical judgment, not the end of one.

This article is educational and not medical advice; decisions about spirometry and COPD belong with a qualified clinician who can weigh the full picture.